

Democratizing Biomanufacturing of Recombinant Proteins & Subunit Vaccines

Dr. Kerry R. Love
CEO, Sunflower Therapeutics PBC
Presented at DCVMN Annual Meeting

September 21, 2023



Sunflower is an early-stage company delivering next-generation biomanufacturing solutions to global innovators servicing a >\$500B market for protein medicines, vaccines and food.

Just like anyone can grow sunflowers anywhere, our solutions are easy to use and empower anyone to efficiently make proteins anywhere.

Our Goal: Make Protein Manufacturing More Accessible



Accessibility

=

Easy to obtain

+

Easy to use



- Lower cost
- Small footprint
- Deployable in simple facilities



- Simple
- Automated
- Efficient
- Flexible (multi-product)
- Scalable

Sunflower Manufacturing Systems: Automated Hardware to Enable Capacity Anywhere




DAISY Petal™

Discovery/R&D

Continuous Fermentation
(up to grams per week)

Taking orders now!




DAHLIA Petal™

Translational Development

Continuous Fermentation
(up to 100s of grams per week)

Early access launch in 2024



DAHLIA™ System


Efficient Commercial Production

Protein Bulk Production
(up to 10 kg annually in <50m²)

Early access launch in 2025


SUNFLOWER'S INTUITIVE APPROACH FACILITATES PROCESS TRANSFERS & SCALING

One Investment for a Flexible Formulary




PLATFORMABLE PROCESSES

using integrated and continuous techniques



NEXT-GENERATION EQUIPMENT

single-use consumables for rapid process transitions



MULTI-PRODUCT FLEXIBLE CAPACITY

for business agility and sustainability



Visit us at:
www.sunflowertx.com

SCAN ME

Sunflower
T H E R A P E U T I C S

Contact:
kerry@sunflowertx.com